Cancer stem cells: The development of new cancer therapeutics

Expert Opinion on Biological Therapy

Volumn 11, Issue 7, 2011, Pages 875-892

  Scatena, Roberto ^a   Bottoni, Patrizia ^a   Pontoglio, Alessandro ^a   Giardina, Bruno ^a  

^a CATHOLIC UNIVERSITY   (Italy)

Author keywords

biomarkers; cancer cell metabolism; cancer therapeutics; circulating tumor cells; dormancy; epigenetic; hedgehog; metastasis; minimal residual disease; notch; resistance to therapy; stem cell niche; telomerase; Wnt

Indexed keywords

1 (1 CYANO 1 METHYLETHYL) 3 METHYL 8 (3 QUINOLINYL)IMIDAZO[4,5 C]QUINOLIN 2(1H,3H) ONE; ACETYLSALICYLIC ACID; ADECATUMUMAB; BETA CATENIN; BISPECIFIC ANTIBODY; BIVATUZUMAB MERTANSINE; CD123 ANTIGEN; CEDIRANIB; CELECOXIB; CELL SURFACE MARKER; DASATINIB; DOCETAXEL; DOFEQUIDAR; EPITHELIAL CELL ADHESION MOLECULE; GAMMA SECRETASE INHIBITOR; GEMTUZUMAB; GEMTUZUMAB OZOGAMICIN; HERMES ANTIGEN; IMATINIB; IMETELSTAT; LAPATINIB; MK 0752; MT 110; PF 03084014; RO 4929097; SUNITINIB; UNCLASSIFIED DRUG; UNINDEXED DRUG; VANDETANIB; VISMODEGIB; WNT PROTEIN;

ADVANCED CANCER; BONE MARROW SUPPRESSION; BREAST METASTASIS; CANCER STEM CELL; CANCER THERAPY; CELL DIFFERENTIATION; CELL METABOLISM; CHRONIC MYELOID LEUKEMIA; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG MECHANISM; DRUG RECALL; DRUG SAFETY; DRUG TARGETING; FEVER; GASTROINTESTINAL STROMAL TUMOR; HAND FOOT SYNDROME; HUMAN; KIDNEY CANCER; KIDNEY CARCINOMA; LUNG NON SMALL CELL CANCER; MOLECULARLY TARGETED THERAPY; NAUSEA; NEUROENDOCRINE TUMOR; NONHUMAN; PANCREAS TUMOR; PATHOPHYSIOLOGY; RESPIRATORY TRACT DISEASE; REVIEW; SHIVERING; SIGNAL TRANSDUCTION; SKIN TOXICITY; STEM CELL NICHE; STOMATITIS; THROMBOSIS; TUMOR LYSIS SYNDROME; VEIN OCCLUSION; VOMITING;

ANIMALS; ANTINEOPLASTIC AGENTS; CELL DIFFERENTIATION; CELL PROLIFERATION; HUMANS; MOLECULAR TARGETED THERAPY; NEOPLASMS; NEOPLASTIC STEM CELLS; PHENOTYPE; SIGNAL TRANSDUCTION; STEM CELL NICHE; TUMOR MARKERS, BIOLOGICAL; TUMOR MICROENVIRONMENT;

ERINACEIDAE;

EID: 79958046684     PISSN: 14712598     EISSN: None     Source Type: Journal    
DOI: 10.1517/14712598.2011.573780     Document Type: Review

References (148)

1. Wang JCY, Dick JE. Cancer stem cells. In: DeVita VT, Lawrence TS, Rosenberg SA, editors, Devita, Hellman & Rosenberg's cancer: principles & practice of oncology. 8th edition. Lippincott Williams & Wilkins, Philadelphia, PA, USA; 2008. p. 135-43
2. Zhou BB, Zhang H, Damelin M, et al. Tumour-initiating cells: challenges and opportunities for anticancer drug discovery. Nat Rev Drug Discov 2009;8:806-23
3. Jordan CT, Guzman ML, Noble M. Cancer stem cells. N Engl J Med 2006;355:1253-61 (Pubitemid 44427449)
4. Trumpp A, Wiestler OD. Mechanisms of disease: cancer stem cells-targeting the evil twin. Nat Clin Pract Oncol 2008;5:337-47 (Pubitemid 351780950)
5. Reya T, Morrison SJ, Clarke MF, Weissman IL. Stem cells, cancer, and cancer stem cells. Nature 2001;414:105-11 (Pubitemid 33041634)
6. Bjerkvig R, Tysnes BB, Aboody KS, et al. Opinion: the origin of the cancer stem cell: current controversies and new insights. Nat Rev Cancer 2005;5:899-904 (Pubitemid 41746034)
7. Bonnet D, Dick JE. Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell. Nat Med 1997;3:730-7 (Pubitemid 27298715)
8. Gan OI, Murdoch B, Larochelle A, Dick JE. Differential maintenance of primitive human SCID-repopulating cells, clonogenic progenitors, and long-term culture-initiating cells after incubation on human bone marrow stromal cells. Blood 1997;90:641-50 (Pubitemid 27299104)
9. Dick JE. Stem cell concepts renew cancer research. Blood 2008;112:4793-807
10. Gupta PB, Chaffer CL, Weinberg RA. Cancer stem cells: mirage or reality? Nat Med 2009;15:1010-12
11. Shackleton M, Quintana E, Fearon ER, Morrison SJ. Heterogeneity in cancer: cancer stem cells versus clonal evolution. Cell 2009;138:822-9
12. Mittal S, Mifflin R, Powell DW. Cancer stem cells: the other face of Janus. Am J Med Sci 2009;338:107-12
13. Tang C, Ang BT, Pervaiz S. Cancer stem cell: target for anti-cancer therapy. FASEB J 2007;21:3777-85 (Pubitemid 350232335)
14. Levitzki A. Tyrosine kinases as targets for cancer therapy. Eur J Cancer 2002;38(Suppl 5):S11-18
15. Bonnet D, Dick JE. Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell. Nat Med 1997;3:730-7 (Pubitemid 27298715)
16. Blair A, Hogge DE, Ailles LE, et al. Lack of expression of Thy-1 (CD90) on acute myeloid leukemia cells with long-term proliferative ability in vitro and in vivo. Blood 1997;89:3104-12 (Pubitemid 27229792)
17. Jordan CT, Upchurch D, Szilvassy SJ, et al. The interleukin-3 receptor alpha chain is a unique marker for human acute myelogenous leukemia stem cells. Leukemia 2000;14:1777-84
18. Jin L, Lee EM, Ramshaw HS, et al. Monoclonal antibody-mediated targeting of CD123, IL-3 receptor alpha chain, eliminates human acute myeloid leukemic stem cells. Cell Stem Cell 2009;5:31-42
19. O'Sullivan B, Thomas R. Recent advances on the role of CD40 and dendritic cells in immunity and tolerance. Curr Opin Hematol 2004;10:272-8 (Pubitemid 36724350)
20. Charrad RS, Gadhoum Z, Qi J, et al. Effects of anti-CD44 monoclonal antibodies on differentiation and apoptosis of human myeloid leukemia cell lines. Blood 2002;99:290-9
21. Gadhoum Z, Delaunay J, Maquarre E, et al. The effect of anti-CD44 monoclonal antibodies on differentiation and proliferation of human acute myeloid leukemia cells. Leuk Lymphoma 2004;45:1501-10 (Pubitemid 38885991)
22. Jin L, Hope KJ, Zhai Q, et al. Targeting of CD44 eradicates human acute myeloid leukemic stem cells. Nat Med 2006;12:1167-74 (Pubitemid 44527352)
23. Al-Hajj M, Wicha MS, Benito-Hernandez A, et al. Prospective identification of tumorigenic breast cancer cells. Proc Natl Acad Sci USA 2003;100:3983-8 .. The first report, to our knowledge, on the origin of CSCs in solid tumors. (Pubitemid 36418143)
24. Subramaniam V, Vincent IR, Gilakjan M, Jothy S. Suppression of human colon cancer tumors in nude mice by siRNA CD44 gene therapy. Exp Mol Pathol 2007;83:332-40 (Pubitemid 350087029)
25. Marangoni E, Lecomte N, Durand L, et al. CD44 targeting reduces tumour growth and prevents post-chemotherapy relapse of human breast cancers xenografts. Br J Cancer 2009;100:918-22
26. Evtimov VJ, Brown TJ. HA-Irinotecan targeting of activated CD44 is an effective therapy for the eradication of putative colon cancer stem cells. Cancer stem cell therapeutics, American Association of Cancer Research (AACR) 101st Annual Meeting in Washington, DC; 2010. Available from: http://www. abstractsonline.com/Plan/start.aspx
27. Entimov VJ, Brown TJ. Evaluation of activated CD44 as a biological target in the eradication of breast cancer stem cells. Cancer stem cell therapeutics, American Association of Cancer Research (AACR) 101st Annual Meeting in Washington, DC; 2010. Available from: http://www.abstractsonline.com/Plan/ start.aspx
28. Bross PF, Beitz J, Chen G, et al. Approval summary: gemtuzumab ozogamicin in relapsed acute myeloid leukemia. Clin Cancer Res 2001;7:1490-6 (Pubitemid 32708610)
29. Clarke WT, Marks PW. Gemtuzumab ozogamicin: is there room for salvage? Blood 2010;116:2618-19
30. Halsen G, Kramer I. Assessing the risk to health care staff from long-term exposure to anticancer drugs - the case of monoclonal antibodies. J Oncol Pharm Pract 2011;17:68-80
31. Koppe M, Schaijk F, Roos J, et al. Safety, pharmacokinetics, immunogenicity, and biodistribution of 186Re-labeled humanized monoclonal antibody BIWA 4 (Bivatuzumab) in patients with early-stage breast cancer. Cancer Biother Radiopharm 2004;19:720-9 (Pubitemid 40279580)
32. Rupp U, Schoendorf-Holland E, Eichbaum M, et al. Safety and pharmacokinetics of bivatuzumab mertansine in patients with CD44v6-positive metastatic breast cancer: final results of a phase I study. Anticancer Drugs 2007;18:477-85 (Pubitemid 46712412)
33. Munz M, Baeuerle PA, Gires O. The emerging role of EpCAM in cancer and stem cell signaling. Cancer Res 2009;69:5627-9
34. Gires O, Klein CA, Baeuerle PA. On the abundance of EpCAM on cancer stem cells. Nat Rev Cancer 2009;9:143
35. Brischwein K, Schlereth B, Guller B, et al. MT110: a novel bispecific single-chain antibody construct with high efficacy in eradicating established tumors. Mol Immunol 2006;43:1129-43 (Pubitemid 43063166)
36. Osada T, Hsu D, Hammond S, et al. Metastatic colorectal cancer cells from patients previously treated with chemotherapy are sensitive to T-cell killing mediated by CEA/CD3-bispecific T-cell-engaging BiTE antibody. Br J Cancer 2010;102:124-33
37. Münz M, Murr A, Kvesic M, et al. Side-by-side analysis of five clinically tested anti-EpCAM monoclonal antibodies. Cancer Cell Int 2010;10:44
38. Amann M, D'Argouges S, Lorenczewski G, et al. Antitumor activity of an EpCAM/CD3-bispecific BiTE antibody during long-term treatment of mice in the absence of T-cell anergy and sustained cytokine release. J Immunother 2009;32:452-64
39. Baeuerle PA, Kufer P, Bargou R. BiTE: teaching antibodies to engage T-cells for cancer therapy. Curr Opin Mol Ther 2009;11:22-30
40. Schuler M, Hanusch C, Steger GG, et al. First results from a phase Ib study of the anti-EpCAM antibody adecatumumab (MT201) in combination with docetaxel in patients with metastatic breast cancer [abstract No 485p]. Annual Meeting of ESMO, 2008
41. Agrawal M, Garg RJ, Cortes J, Quintas-Cardama A. Tyrosine kinase inhibitors: the first decade. Curr Hematol Malig Rep 2010;5:70-80
42. Naka K, Hoshii T, Hirao A. Novel therapeutic approach to eradicate tyrosine kinase inhibitor resistant chronic myeloid leukemia stem cells. Cancer Sci 2010;101:1577-81
43. Mustjoki S, Rohon P, Rapakko K, et al. Low or undetectable numbers of Philadelphia chromosome-positive leukemic stem cells (Ph+CD34 +CD38neg) in chronic myeloid leukemia patients in complete cytogenetic remission after tyrosine kinase inhibitor therapy. Leukemia 2010;24:219-22
44. Norwegian University of Science and Technology. Randomized Study Comparing the Effect of Dasatinib and Imatinib on Malignant Stem Cells in Chronic Myeloid Leukemia (NordCML006) ClinicalTrials.gov NCT00852566. Available from: http:// clinicaltrials.gov/show/NCT00852566
45. Roesler R, Cornelio DB, Abujamra AL, Schwartsmann G. HER2 as a cancer stem-cell target. Lancet Oncol 2010;11:225-6
46. Wicha MS. Targeting breast cancer stem cells. Breast 2009;18(Suppl 3):S56-8
47. Diaz R, Nguewa PA, Parrondo R, et al. Antitumor and antiangiogenic effect of the dual EGFR and HER-2 tyrosine kinase inhibitor lapatinib in a lung cancer model. BMC Cancer 2010;10:188
48. Mimeault M, Johansson SL, Henichart JP, et al. Cytotoxic effects induced by docetaxel, gefitinib, and cyclopamine on side population and non side population cell fractions from human invasive prostate cancer cells. Mol Cancer Ther 2010;9:617-30
49. Croom KF, Perry CM. Imatinib mesylate: in the treatment of gastrointestinal stromal tumours. Drugs 2003;63:513-22 (Pubitemid 36337730)
50. Griffero F, Daga A, Marubbi D, et al. Different response of human glioma tumor-initiating cells to epidermal growth factor receptor kinase inhibitors. J Biol Chem 2009;284:7138-48
51. Cantley L, Carpenter CL. Cell signaling. In: DeVita VT, Theodore L, Rosenberg SA, editors, Devita, Hellman & Rosenberg's cancer: principles & practice of oncology. 8th edition. Lippincott Williams & Wilkins, Philadelphia, PA, USA; 2008, p 67-76
52. Reya T, Clevers H. Wnt signalling in stem cells and cancer. Nature 2005;434:843-50 (Pubitemid 40558990)
53. Takahashi-Yanaga F, Kahn M. Targeting Wnt signaling: can we safely eradicate cancer stem cells? Clin Cancer Res 2010;16:3153-62
54. Redova M, Chlapek P, Loja T, et al. Influence of LOX/COX inhibitors on cell differentiation induced by all-trans retinoic acid in neuroblastoma cell lines. Int J Mol Med 2010;25:271-80
55. Roccaro AM, Leleu X, Sacco A, et al. Resveratrol exerts antiproliferative activity and induces apoptosis in Waldenstr€om's macroglobulinemia. Clin Cancer Res 2008;14:1849-58 (Pubitemid 351469472)
56. Vanamala J, Reddivari L, Radhakrishnan S, Tarver C. Resveratrol suppresses IGF-1 induced human colon cancer cell proliferation and elevates apoptosis via suppression of IGF-1R/Wnt and activation of p53 signaling pathways. BMC Cancer 2010;10:238
57. Emami KH, Nguyen C, Ma H, et al. A small molecule inhibitor of betacatenin/ CREB-binding protein transcription. Proc Natl Acad Sci USA 2004;101:12682-7 (Pubitemid 39122083)
58. Bos CL, Kodach LL, van den Brink GR, et al. Effect of aspirin on the Wnt/betacatenin pathway is mediated via protein phosphatase 2A. Oncogene 2006;25:6447-56 (Pubitemid 44607077)
59. Deng L, Hu S, Baydoun AR, et al. Aspirin induces apoptosis in mesenchymal stem cells requiring Wnt/beta-catenin pathway. Cell Prolif 2009;42:721-30
60. Wang Y, Chen X, Zhu W, et al. Growth inhibition of mesenchymal stem cells by aspirin: involvement of the WNT/beta-catenin signal pathway. Clin Exp Pharmacol Physiol 2006;33:696-701 (Pubitemid 44060760)
61. Razavi R, Gehrke I, Gandhirajan RK, et al. Nitric oxide-donating acetylsalicylic acid induces apoptosis in chronic lymphocytic leukemia cells and shows strong antitumor efficacy in vivo. Clin Cancer Res 2011;17:286-93
62. Chen KH, Hsu CC, Song WS, et al. Celecoxib enhances radiosensitivity in medulloblastoma-derived CD133-positive cells. Childs Nerv Syst 2010;26:1605-12
63. Singh B, Cook KR, Vincent L, et al. Role of COX-2 in tumorospheres derived from a breast cancer cell line. J Surg Res 2010: published online 26 Mar 2010, doi:10.1016/j.jss.2010.03.003
64. Kang KB, Wang TT, Woon CT, et al. Enhancement of glioblastoma radioresponse by a selective COX-2 inhibitor celecoxib: inhibition of tumor angiogenesis with extensive tumor necrosis. Int J Radiat Oncol Biol Phys 2007;67:888-96 (Pubitemid 46215892)
65. Kim H, Won S, Hwang DY, et al. Downregulation of Wnt/beta-catenin signaling causes degeneration of hippocampal neurons in vivo. Neurobiol Aging 2010: published online 19 April 2010, doi:10.1016/j.neurobiolaging. 2010.03.013
66. Chen X, Deng Y. Simulations of a specific inhibitor of the dishevelled PDZ domain. J Mol Model 2009;15:91-6
67. He B, You L, Uematsu K, et al. A monoclonal antibody against Wnt-1 induces apoptosis in human cancer cells. Neoplasia 2004;6:7-14 (Pubitemid 38391944)
68. You L, He B, Xu Z, et al. An anti-Wnt-2 monoclonal antibody induces apoptosis in malignant melanoma cells and inhibits tumor growth. Cancer Res 2004;64:5385-9 (Pubitemid 39006560)
69. He B, Lee AY, Dadfarmay S, et al. Secreted frizzled-related protein 4 is silenced by hypermethylation and induces apoptosis in beta-catenin-deficient human mesothelioma cells. Cancer Res 2005;65:743-8 (Pubitemid 40216431)
70. King PJ, Guasti L, Laufer E. Hedgehog signalling in endocrine development and disease. J Endocrinol 2008;198:439-50
71. Von Hoff DD, LoRusso PM, Rudin CM, et al. Inhibition of the hedgehog pathway in advanced basal-cell carcinoma. N Engl J Med 2009;361:1164-72 .. A valuable clinical study on a hedgehog pathway inhibitor.
72. Yauch RL, Dijkgraaf GJ, Alicke B, et al. Smoothened mutation confers resistance to a Hedgehog pathway inhibitor in medulloblastoma. Science 2009;326:572-4 .. A fundamental report on acquired resistance to Hedgehog pathway inhibitor.
73. Zibat A, Missiaglia E, Rosenberger A, et al. Activation of the hedgehog pathway confers a poor prognosis in embryonal and fusion gene-negative alveolar rhabdomyosarcoma. Oncogene 2010;29:6323-30
74. Merchant AA, Matsui W. Targeting Hedgehog - a cancer stem cell pathway. Clin Cancer Res 2010;16:3130-40
75. So PL, Tang JY, Epstein EH. Novel investigational drugs for basal cell carcinoma. Expert Opin Investig Drugs 2010;19:1099-112
76. Doggrell SA. The hedgehog pathway inhibitor GDC-0449 shows potential in skin and other cancers. Expert Opin Investig Drugs 2010;19:451-4
77. Rudin CM, Hann CL, Laterra J, et al. Treatment of medulloblastoma with hedgehog pathway inhibitor GDC-0449. N Engl J Med 2009;361:1173-8
78. University of Chicago. Gemcitabine hydrochloride with or without GDC-0449 in treating patients with recurrent or metastatic pancreatic cancer. ClinicalTrials.gov NCT01064622. Available from: http://clinicaltrials.gov/ show/NCT01064622
79. Barbara Ann Karmanos Cancer Institute GDC-0449 and RO4929097 in treating women with advanced breast cancer. ClinicalTrials.gov NCT01071564 Available from: http://clinicaltrials.gov/ show/NCT01071564
80. Sidney Kimmel Comprehensive Cancer Center. Hedgehog inhibitors for metastatic adenocarcinoma of the pancreas. ClinicalTrials.gov NCT01088815. Available from: http:// clinicaltrials.gov/show/NCT01088815
81. University of Michigan Cancer Center Cancer Stem Cells and inhibition of hedgehog pathway signaling in advanced pancreas cancer: a pilot study of GDC-0449 in combination with gemcitabine. ClinicalTrials.gov NCT01195415 Available from: http:// clinicaltrials.gov/show/NCT01195415
82. Genentech, Inc. A study of GDC-0449 (hedgehog gathway inhibitor) in patients treated with GDC-0449 in a previous Genentech-sponsored phase I or II cancer study. ClinicalTrials.gov NCT00959647. Available from: http://clinicaltrials.gov/ show/NCT00959647
83. Yauch RL, Dijkgraaf GJ, Alicke B, et al. Smoothened mutation confers resistance to a hedgehog pathway inhibitor in medulloblastoma. Science 2009;326:572-4
84. Hidalgo M, Maitra A. The hedgehog pathway and pancreatic cancer N Engl J Med 2009;361:2094-6
85. Infinity Pharmaceuticals. A phase 1 study of IPI-926 in patients with advanced and/or metastatic solid tumor malignancies. ClinicalTrials.gov NCT00761696. Available from: http:// clinicaltrials.gov/show/NCT00761696
86. Bolos V, Grego-Bessa J, de la Pompa JL. Notch signaling in development and cancer. Endocr Rev 2007;28:339-63 (Pubitemid 46984831)
87. Pannuti A, Foreman K, Rizzo P, Osipo C. Targeting Notch to target cancer stem cells. Clin Cancer Res 2010;16:3141-52
88. Koch U, Radtke F. Notch signaling in solid tumors. Curr Top Dev Biol 2010;92:411-55
89. Yin L, Velazquez OC, Liu ZJ. Notch signaling: emerging molecular targets for cancer therapy. Biochem Pharmacol 2010;80:690-701
90. Merck. A Notch Signalling Pathway Inhibitor for Patients With T-cell Acute Lymphoblastic Leukemia/Lymphoma (ALL). ClinicalTrials.gov NCT00100152. Available from: http:// clinicaltrials.gov/show/NCT00100152
91. Merck. A Study of Dalotuzumab + MK-2206 and Dalotuzumab + MK-0752 Combination Therapies in Participants With Advanced Cancer (MK-0646-027). ClinicalTrials. gov NCT01243762. Available from: http://clinicaltrials.gov/show/ NCT01243762
92. University of Michigan Cancer Center. Phase I/II Study of MK-0752 Followed by Docetaxel in Advanced or Metastatic Breast Cancer. ClinicalTrials.gov NCT00645333. Available from: http:// clinicaltrials.gov/ct2/ show/NCT00645333
93. Luistro L, He W, Smith M, et al. Preclinical profile of a potent gamma-secretase inhibitor targeting notch signaling with in vivo efficacy and pharmacodynamic properties. Cancer Res 2009;69:7672-80
94. M.D. Anderson Cancer Center. RO4929097 in treating patients with advanced non-small cell lung cancer who are progression-free after finishing treatment with front-line chemotherapy. ClinicalTrials.gov NCT01193868. Available from: http://clinicaltrials.gov/ct2/show/NCT01193868
95. University of Chicago. RO4929097 Before surgery in treating patients with pancreatic cancer ClinicalTrials.gov NCT01192763. Available from: http://clinicaltrials.gov/ ct2/show/NCT01192763
96. Albert Einstein College of Medicine of Yeshiva University. RO4929097 in treating patients with stage IIIB, stage IIIC, or stage IV melanoma that can be removed by surgery. ClinicalTrials.gov NCT01216787. Available from: http:// clinicaltrials.gov/ct2/show/NCT01216787
97. Wu Y, Cain-Hom C, Choy L, et al. Therapeutic antibody targeting of individual Notch receptors. Nature 2010;464:1052-9
98. Hoey T, Yen WC, Axelrod F, et al. 1DLL4 blockade inhibits tumor growth and reduces tumor-initiating cell frequency. Cell Stem Cell 2009;5:168-77
99. OncoMed Pharmaceuticals, Inc. A Study of Gemcitabine Plus OMP-21M18 as 1st-line Treatment in Subjects with Pancreatic Cancer. ClinicalTrials.gov NCT01189929. Available from: http:// clinicaltrials.gov/ct2/show/NCT01189929
100. OncoMed Pharmaceuticals, Inc. A Study of FOLFIRI Plus OMP-21M18 as 1st or 2nd-line Treatment in Subjects with Metastatic Colorectal Cancer. ClinicalTrials.gov NCT01189942. Available from: http://clinicaltrials.gov/ ct2/show/NCT01189942
101. OncoMed Pharmaceuticals, Inc. A Study of Carboplatin and Pemetrexed Plus OMP-21M18 in Subjects with Non-Squamous Non-Small Cell Lung Cancer. ClinicalTrials.gov NCT01189968. Available from: http:// clinicaltrials.gov/ct2/ show/NCT01189968
102. Wei P, Walls M, Qiu M, et al. Evaluation of selective gamma-secretase inhibitor PF-03084014 for its antitumor efficacy and gastrointestinal safety to guide optimal clinical trial design. Mol Cancer Ther 2010;9:1618-28
103. Deonarain MP, Kousparou CA, Epenetos AA. Antibodies targeting cancer stem cells: a new paradigm in immunotherapy? MAbs 2009;1:12-25
104. van der Heijden MS, Bernards R. Inhibition of the PI3K pathway: hope we can believe in? Clin Cancer Res 2010;16:3094-9
105. Scatena R, Bottoni P, Pontoglio A, Giardina B. Revisiting the Warburg effect in cancer cells with proteomics. The emergence of new approaches to diagnosis, prognosis and therapy. Proteomics Clin Appl 2010:4143-58
106. Murphy CG, Fornier M. HER2-positive breast cancer: beyond trastuzumab. Oncology (Williston Park) 2010;24:410-15
107. LoRusso PM, Ryan AJ, Boerner SA. Small molecule tyrosine kinase inhibitors. In: DeVita VT, Lawrence TS, Rosenberg SA, editors, Devita, Hellman & Rosenberg's cancer: principles & practice of oncology. 8th edition. Lippincott Williams & Wilkins. Philadelphia, PA, USA; 2008. p. 457-91
108. University of Maryland. Vorinostat and Lapatinib in advanced solid tumors and advanced breast cancer to evaluate response and biomarkers. ClinicalTrials. gov NCT01118975. Available from: http://clinicaltrials.gov/ct2/show/ NCT01118975
109. Deng Y, Chan SS, Chang S. Telomere dysfunction and tumour suppression: the senescence connection. Nat Rev Cancer 2008;8:450-8 (Pubitemid 351744962)
110. Castelo-Branco P, Zhang C, Lipman T, et al. Neural tumor-initiating cells have distinct telomere maintenance and can be safely targeted for telomerase inhibition. Clin Cancer Res 2011;17:111-21
111. Joseph I, Tressler R, Bassett E, et al. The telomerase inhibitor imetelstat depletes cancer stem cells in breast and pancreatic cancer cell lines. Cancer Res 2010;70:9494-504
112. Brennan SK, Wang Q, Tressler R, et al. Telomerase inhibition targets clonogenic multiple myeloma cells through telomere length-dependent and independent mechanisms. PLoS One 2010;5:e12487
113. Marian CO, Cho SK, McEllin BM, et al. The telomerase antagonist, imetelstat, efficiently targets glioblastoma tumor-initiating cells leading to decreased proliferation and tumor growth. Clin Cancer Res 2010;16:154-63
114. Geron Corp. Imetelstat as maintenance therapy after initial induction chemotherapy in non-small cell lung cancer (NSCLC). ClinicalTrials.gov NCT01137968. Available from: http:// clinicaltrials.gov/ct2/show/NCT01137968
115. Butler JM, Kobayashi H, Rafii S. Instructive role of the vascular niche in promoting tumour growth and tissue repair by angiocrine factors. Nat Rev Cancer 2010;10:138-46
116. LaBarge MA. The difficulty of targeting cancer stem cell niches. Clin Cancer Res 2010;16:3121-9
117. Ramalingam SS, Belani CP, Mack PC, et al. Phase II study of Cediranib (AZD 2171), an inhibitor ofthe vascular endothelial growth factor receptor, for second-line therapy of small cell lung cancer (National Cancer Institute #7097). J Thorac Oncol 2010;5:1279-84
118. van Cruijsen H, Voest EE, Punt CJ, et al. Phase I evaluation of cediranib, a selective VEGFR signalling inhibitor, in combination with gefitinib in patients with advanced tumours. Eur J Cancer 2010;46:901-11
119. Batchelor TT, Duda DG, di Tomaso E, et al. Phase II study of cediranib, an oral pan-vascular endothelial growth factor receptor tyrosine kinase inhibitor, in patients with recurrent glioblastoma. J Clin Oncol 2010;28:2817-23
120. Goodwin R, Ding K, Seymour L, et al. Treatment-emergent hypertension and outcomes in patients with advanced non-small-cell lung cancer receiving chemotherapy with or without the vascular endothelial growth factor receptor inhibitor cediranib: NCIC Clinical Trials Group Study BR24. Ann Oncol 2010;21:2220-6
121. Recentin disappoints in colorectal cancer. Chichester, UK: InPharm.com, 2010. Available from: http://www. inpharm.com/news/recentin- disappointscolorectal- cancer
122. Zama IN, Hutson TE, Elson P, et al. Sunitinib rechallenge in metastatic renal cell carcinoma patients. Cancer 2010;116:5400-6
123. Younus J, Verma S, Franek J, Coakley N. Sunitinib malate for gastrointestinal stromal tumour in imatinib mesylate-resistant patients: recommendations and evidence. Curr Oncol 2010;17:4-10
124. Neyns B, Sadones J, Chaskis C, et al. Phase II study of sunitinib malate in patients with recurrent high-grade glioma. J Neurooncol 2010: published online 25 September 2010, doi:
125. Shojaei F, Lee JH, Simmons BH, et al. HGF/c-Met acts as an alternative angiogenic pathway in sunitinib-resistant tumors. Cancer Res 2010;70:10090-100
126. Phay JE, Shah MH. Targeting RET receptor tyrosine kinase activation in cancer. Clin Cancer Res 2010;16:5936-41
127. Fletcher JI, Haber M, Henderson MJ, Norris MD. ABC transporters in cancer: more than just drug efflux pumps. Nat Rev Cancer 2010;10:147-56
128. Katayama R, Koike S, Sato S, et al. Dofequidar fumarate sensitizes cancer stem-like side population cells to chemotherapeutic drugs by inhibiting ABCG2/BCRP-mediated drug export. Cancer Sci 2009;100:2060-8
129. Yoshikawa D, Ojima H, Kokubu A, et al. Vandetanib (ZD6474), an inhibitor of VEGFR and EGFR signalling, as a novel molecular-targeted therapy against cholangiocarcinoma. Br J Cancer 2009;100:1257-66
130. Zheng LS, Wang F, Li YH, et al. Vandetanib (Zactima, ZD6474) antagonizes ABCC1- and ABCG2-mediated multidrug resistance by inhibition of their transport function. PLoS One 2009;4:e5172
131. Kitazaki T, Oka M, Nakamura Y, et al. Gefitinib, an EGFR tyrosine kinase inhibitor, directly inhibits the function of P-glycoprotein in multidrug resistant cancer cells. Lung Cancer 2005;49:337-43 (Pubitemid 41139146)
132. Tao LY, Liang YJ, Wang F, et al. Cediranib (recentin, AZD2171) reverses ABCB1- and ABCC1-mediated multidrug resistance by inhibition of their transport function. Cancer Chemother Pharmacol 2009;64:961-9
133. Gupta PB, Onder TT, Jiang G, et al. Identification of selective inhibitors of cancer stem cells by high-throughput screening. Cell 2009;138:645-59
134. Riccioni R, Dupuis ML, Bernabei M, et al. The cancer stem cell selective inhibitor salinomycin is a p-glycoprotein inhibitor. Blood Cells Mol Dis 2010;45:86-92
135. Massard C, Deutsch E, Soria JC. Tumour stem cell-targeted treatment: elimination or differentiation. Ann Oncol 2006;17:1620-4 (Pubitemid 44680880)
136. Scatena R, Bottoni P, Giardina B. Modulation of cancer cell line differentiation: a neglected proteomic analysis with potential implications in pathophysiology, diagnosis, prognosis, and therapy of cancer. Proteomics Clin Appl 2008;2:229-37 (Pubitemid 351284902)
137. Nowak D, Stewart D, Koeffler HP. Differentiation therapy of leukemia: 3 decades of development. Blood 2009;113:3655-65
138. Rosato RR, Grant S. Histone deacetylase inhibitors in clinical development. Expert Opin Investig Drugs 2004;13:21-38 (Pubitemid 38111432)
139. Atadja PW. HDAC inhibitors and cancer therapy. Prog Drug Res 2011;67:175-95
140. Martinez-Iglesias O, Ruiz-Llorente L, Sanchez-Martinez R, et al. Histone deacetylase inhibitors: mechanism of action and therapeutic use in cancer. Clin Transl Oncol 2008;10:395-8
141. Marks PA. Discovery and development of SAHA as an anticancer agent. Oncogene 2007;26:1351-6 (Pubitemid 46328465)
142. Bottoni P, Giardina B, Martorana GE, et al. A two-dimensional electrophoresis preliminary approach to human hepatocarcinoma differentiation induced by PPAR-agonists. J Cell Mol Med 2005;9:462-7
143. Scatena R, Bottoni P, Giardina B. Mitochondria, PPARs, and cancer: is receptor-independent action of PPAR agonists a key? PPAR Res 2008;2008:256251
144. Khanim FL, Hayden RE, Birtwistle J, et al. Combined bezafibrate and medroxyprogesterone acetate: potential novel therapy for acute myeloid leukaemia. PLoS One 2009;4:e8147
145. Murray JA, Khanim FL, Hayden RE, et al. Combined bezafibrate and medroxyprogesterone acetate have efficacy without haematological toxicity in elderly and relapsed acute myeloid leukaemia (AML). Br J Haematol 2010;149:65-9
146. Wang R, Chadalavada K, Wilshire J, et al. Glioblastoma stem-like cells give rise to tumour endothelium. Nature 2010;468:829-33
147. Ricci-Vitiani L, Pallini R, Biffoni M, et al. Tumour vascularization via endothelial differentiation of glioblastoma stem-like cells. Nature 2010;468:824-8
148. Janic A, Mendizabal L, Llamazares S, et al. Ectopic expression of germline genes drives malignant brain tumor growth in Drosophila. Science 2010;330:1824-7